These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4834616)

  • 1. Pharmacokinetic studies with an isoniazid slow-releasing matrix preparation.
    Eidus L; Hodgkin MM; Hsu AH; Schaefer O
    Am Rev Respir Dis; 1974 Jul; 110(1):34-42. PubMed ID: 4834616
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of various isoniazid slow releasing matrix preparations for intermittent chemotherapy of tuberculosis.
    Hodgkin MM; Eidus L; Hershfield ES
    Res Commun Chem Pathol Pharmacol; 1979 May; 24(2):349-65. PubMed ID: 461989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosis.
    Ellard GA; Gammon PT; Lakshminarayan S; Fox W; Aber VR; Mitchison DA; Citron KM; Tall R
    Lancet; 1972 Feb; 1(7746):340-3. PubMed ID: 4109735
    [No Abstract]   [Full Text] [Related]  

  • 4. [Concentration of free isoniazid in blood and its urinary excretion in various methods of administration to children with pulmonary tuberculosis].
    Khrůleva TS
    Antibiotiki; 1970 Feb; 15(2):177-81. PubMed ID: 5309795
    [No Abstract]   [Full Text] [Related]  

  • 5. Determination of the acetylator phenotype using matrix isoniazid.
    Ellard GA; Gammon PT; Titinen H
    Tubercle; 1975 Sep; 56(3):203-9. PubMed ID: 1216339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Variability of isoniazid pharmacokinetics].
    Sokolova GB; Ivleva AIa; Ziia AV; Vilenskaia RN
    Farmakol Toksikol; 1982; 45(3):101-4. PubMed ID: 7095118
    [No Abstract]   [Full Text] [Related]  

  • 7. Further studies on the pharmacology of a slow-release matrix preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis.
    Ellard GA; Gammon PT; Polansky F; Víznerová A; Havlík I; Fox W
    Tubercle; 1973 Mar; 54(1):57-66. PubMed ID: 4774935
    [No Abstract]   [Full Text] [Related]  

  • 8. Isoniazid levels in black patients dosed with a matrix preparation (Tebesium).
    Glatthaar E; Gärtig D; Stander MF; Kleeberg HH
    Prax Klin Pneumol; 1977 Oct; 31(10):855-9. PubMed ID: 928288
    [No Abstract]   [Full Text] [Related]  

  • 9. [Isoniazid acetylation among Brazilian Caucasoids and Negroids with pulmonary tuberculosis].
    Beiguelman B; Ramalho AS; Arena JF; Garlipp CR
    Rev Paul Med; 1977; 89(1-2):12-5. PubMed ID: 918481
    [No Abstract]   [Full Text] [Related]  

  • 10. A slow-release preparation of isoniazid: pharmacological aspects.
    Ellard GA
    Bull Int Union Tuberc; 1976; 51(1):144-54. PubMed ID: 1030275
    [No Abstract]   [Full Text] [Related]  

  • 11. Classification of subjects as slow or rapid inactivators of isoniazid, based on the ratio of the urinary excretion of acetylisoniazid to isoniazid.
    Venkataraman P; Menon NK; Nair NG; Radhakrishna S; Ross C; Tripathy SP
    Indian J Med Res; 1972 May; 60(5):685-93. PubMed ID: 4663236
    [No Abstract]   [Full Text] [Related]  

  • 12. Determination of acetylator phenotype based on the ratio of acetylisoniazid to isoniazid in urine following an oral dose of ordinary isoniazid.
    Raghupati Sarma G; Kannapirin G; Narayana AS; Radhakrishna S; Tripathy SP
    Indian J Med Res; 1976 Jan; 64(1):1-8. PubMed ID: 1270091
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic consequences of measure of inactivation index of isoniazid during antituberculous therapy (author's transl)].
    Houin G; Tillement JP
    Therapie; 1980; 35(5):597-605. PubMed ID: 7209857
    [No Abstract]   [Full Text] [Related]  

  • 14. [Blood and urine INH levels, administered orally alone or combined with proteolytic enzymes].
    Concina E; Penna R; Grattarola M; Spataro C
    G Mal Infett Parassit; 1967 Jul; 19(7):450-1. PubMed ID: 5609921
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin.
    Jenne JW; Beggs WH
    Am Rev Respir Dis; 1973 Jun; 107(6):1013-21. PubMed ID: 4197230
    [No Abstract]   [Full Text] [Related]  

  • 16. [The role of inactivation of phthivazid in the therapy of tuberculosis in children].
    Aminov NR
    Probl Tuberk; 1965; 43(8):29-33. PubMed ID: 5296614
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of pulmonary tuberculosis by the one-time administration of preparations depending on the degree of isonicotinic acid hydrazide inactivation].
    Oliferovskaia RP
    Sov Med; 1972 Apr; 35(4):104-7. PubMed ID: 4662426
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioavailability study with a new isoniazid preparation.
    Eidus L; Hodgkin MM; Hsu AH
    Int J Clin Pharmacol; 1973 Oct; 8(2):154-9. PubMed ID: 4762906
    [No Abstract]   [Full Text] [Related]  

  • 19. [Inactivation of tubazid and its influence on the effectiveness of antibacterial therapy of patients with pulmonary tuberculosis].
    Sumbatov GA; Ioffe RA; Poliakova SG
    Probl Tuberk; 1965; 43(8):23-8. PubMed ID: 5869065
    [No Abstract]   [Full Text] [Related]  

  • 20. [Determination of active isoniazid in the blood serum after intratracheal administration in patients with coniotuberculosis].
    Ryzhkova VV; Kasper GA; Bekembaev RM
    Probl Tuberk; 1973; 51(1):51-4. PubMed ID: 4727159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.